SIRT1 - An anti-inflammatory pathway at the crossroads between metabolic disease and atherosclerosis

Current Vascular Pharmacology

Volumn 10, Issue 6, 2012, Pages 693-696

  Winnik, Stephan ^a,b   Stein, Sokrates ^a,b   Matter, Christian M ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

Atherosclerosis; Inflammation; Sirt1

Indexed keywords

ABC TRANSPORTER A1; ANTHRA [1, 9 CD] PYRAZOL 6 (2H) ONE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CHOLESTEROL; ENDOTHELIAL NITRIC OXIDE SYNTHASE; INTERCELLULAR ADHESION MOLECULE 1; LIVER X RECEPTOR; NITRIC OXIDE; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; REACTIVE OXYGEN METABOLITE; SCAVENGER RECEPTOR; SIRTUIN 1; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CALORIC RESTRICTION; CAROTID ARTERY THROMBOSIS; HUMAN; INFLAMMATION; INSULIN RESISTANCE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; THROMBOSIS; VASODILATATION;

ANIMALS; ATHEROSCLEROSIS; CHOLESTEROL; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; ENZYME ACTIVATORS; HEMOSTASIS; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; METABOLIC DISEASES; SIGNAL TRANSDUCTION; SIRTUIN 1;

EID: 84870211276     PISSN: 15701611     EISSN: 18756212     Source Type: Journal    
DOI: 10.2174/157016112803520756     Document Type: Article

References (33)

1. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-7.
2. Manning AM, Davis RJ. Targeting JNK for therapeutic benefit: from junk to gold? Nat Rev Drug Discov 2003; 2: 554-65.
3. Hirosumi J, Tuncman G, Chang L, et al. A central role for JNK in obesity and insulin resistance. Nature 2002; 420: 333-6.
4. Ricci R, Sumara G, Sumara I, et al. Requirement of JNK2 for scavenger receptor A-mediated foam cell formation in atherogenesis. Science 2004; 306: 1558-61.
5. Osto E, Matter CM, Kouroedov A, et al. c-Jun N-terminal kinase 2 deficiency protects against hypercholesterolemia-induced endothelial dysfunction and oxidative stress. Circulation 2008; 118: 2073-80.
6. von Lukowicz T, Hassa PO, Lohmann C, et al. PARP1 is required for adhesion molecule expression in atherogenesis. Cardiovasc Res 2008; 78: 158-66.
7. Garcia Soriano F, Virag L, Jagtap P, et al. Diabetic endothelial dysfunction: the role of poly(ADP-ribose) polymerase activation. Nat Med 2001; 7: 108-13.
8. Erener S, Hesse M, Kostadinova R, et al. Poly(ADPRibose) Polymerase-1 (PARP1) Controls Adipogenic Gene Expression and Adipocyte Function. Mol Endocrinol 2012; 26: 79-86.
9. Bai P, Canto C, Oudart H, et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab 2011; 13: 461-8.
10. Kaeberlein M, McVey M, Guarente L. The SIR2/3/4 complex and SIR2 alone promote longevity in Saccharomyces cerevisiae by two different mechanisms. Genes Dev 1999; 13: 2570-80.
11. Chen D, Steele AD, Lindquist S, et al. Increase in activity during calorie restriction requires Sirt1. Science 2005; 310: 1641.
12. Bordone L, Motta MC, Picard F, et al. Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells. PLoS Biol 2006; 4: e31.
13. Picard F, Kurtev M, Chung N, et al. Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma. Nature 2004; 429: 771-6.
14. Lagouge M, Argmann C, Gerhart-Hines Z, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1alpha. Cell 2006; 127: 1109-22.
15. Rodgers JT, Lerin C, Haas W, et al. Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1. Nature 2005; 434: 113-8.
16. Yeung F, Hoberg JE, Ramsey CS, et al. Modulation of NF-kappaBdependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 2004; 23: 2369-80.
17. Li X, Zhang S, Blander G, et al. SIRT1 deacetylates and positively regulates the nuclear receptor LXR. Mol Cell 2007; 28: 91-106.
18. Kim I, Moon SO, Kim SH, et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-kappa B activation in endothelial cells. J Biol Chem 2001; 276: 7614-20.
19. O'Brien KD, McDonald TO, Chait A, et al. Neovascular expression of E-selectin, intercellular adhesion molecule-1, and vascular cell adhesion molecule-1 in human atherosclerosis and their relation to intimal leukocyte content. Circulation 1996; 93: 672-82.
20. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
21. Burnett C, Valentini S, Cabreiro F, et al. Absence of effects of Sir2 overexpression on lifespan in C. elegans and Drosophila. Nature 2011; 477: 482-5.
22. Couzin-Frankel J. Genetics. Aging genes: the sirtuin story unravels. Science 2011; 334: 1194-8.
23. Mattagajasingh I, Kim CS, Naqvi A, et al. SIRT1 promotes endothelium-dependent vascular relaxation by activating endothelial nitric oxide synthase. Proc Natl Acad Sci USA 2007; 104: 14855-60.
24. Zhang QJ, Wang Z, Chen HZ, et al. Endothelium-specific overexpression of class III deacetylase SIRT1 decreases atherosclerosis in apolipoprotein E-deficient mice. Cardiovasc Res 2008; 80: 191-9.
25. Orimo M, Minamino T, Miyauchi H, et al. Protective role of SIRT1 in diabetic vascular dysfunction. Arterioscler Thromb Vasc Biol 2009; 29: 889-94.
26. Stein S, Lohmann C, Schafer N, et al. SIRT1 decreases Lox-1-mediated foam cell formation in atherogenesis. Eur Heart J 2010; 31: 2301-9.
27. Stein S, Schafer N, Breitenstein A, et al. SIRT1 reduces endothelial activation without affecting vascular function in ApoE-/-mice. Aging (Albany NY) 2010; 2: 353-60.
28. Breitenstein A, Stein S, Holy EW, et al. Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cells. Cardiovasc Res 2011; 89: 464-72.
29. Milne JC, Lambert PD, Schenk S, et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007; 450: 712-6.
30. Pacholec M, Bleasdale JE, Chrunyk B, et al. SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1. J Biol Chem 2010; 285: 8340-51.
31. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460: 587-91.
32. Guarente L. Franklin H. Epstein Lecture: Sirtuins, aging, and medicine. N Engl J Med 2011; 364: 2235-44.
33. Stein S, Matter CM. Protective roles of SIRT1 in atherosclerosis. Cell Cycle 2011; 10: 640-7.